In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand

European Journal of Nuclear Medicine

Volumn 25, Issue 5, 1998, Pages 471-480

  Milenic, Diane E ^a   Roselli, Mario ^a,b   Brechbiel, Martin W ^a   Pippin, C Greg ^a,c   McMurray, Thomas J ^a,c   Carrasquillo, Jorge A ^d   Colcher, David ^a,e   Lambrecht, Richard ^f   Gansow, Otto A ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c METASyn Inc ^*  (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

B72.3; DOTA; Lead chelates; Monoclonal antibody; Radioimmunoscintigraphy; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CHELATE; LEAD 203; LIGAND; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNOSCINTIGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; RADIOTHERAPY; SCINTIGRAPHY; TUMOR XENOGRAFT;

EID: 15444345418     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050246     Document Type: Article

References (51)

1. Siler K, Eggensberger D, Milenic DE, Miller LS, Houchens DP, Hinkle G, Schlom J. Therapeutic efficacy of a high affinity anti-carcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther 1993; 4: 163-181.
2. Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, Houchens DP, Colcher D. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990; 82: 763-771.
3. 177lutetium-labeled immunoconjugate. Cancer Res 1991; 51: 2889-2896.
4. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, Riva N, Casi M, Moscatelli G, Frattarelli M. Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors. Cancer 1994; 73: 1076-1082.
5. Maraveyas A, Snook D, Hird V, Kosmas C, Meares CF, Lambert HE, Epenetos AA. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994; 73: 1067-1075.
6. 131I-M195 (anti-CD33) for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294-303.
7. DeNardo SJ, O'Grady LF, Richman CM, DeNardo GL. Overview of radioimmunotherapy in advanced cancer using I-131 chimeric L6. Adv Exp Med Biol 1994; 353: 203-211.
8. Schroff RW, Weiden PL, Appelbaum J, Fer MF, Breitz H, Vanderheyden J-L, Ratliff BA, Fisher D, Foisie D, Hanelin LG, Morgan AC Jr, Fritzberg AR, Abrams PG. Rhenium-186 labeled antibody in patients with cancer: report of a pilot phase 1 study. Antibody Immunoconj Radiopharm 1990; 3: 99-111.
9. O'Brien HA Jr. Overview of radionuclides useful for radioimmunoimaging/radioimmunotherapy and current status of preparing radiolabeled antibodies. In: Burchiel SW, Rhodes BA, eds. Radioimmunoimaging and radioimmunotheraphy. New York: Elsevier; 1983: 161-169.
10. Martell AE, Smith RM. Critical stability constants. In: Vol 1: Amino acids. New York: Plenum Press; 1974: 281-284.
11. Chinol M, Hnatowich DJ. Generator produced yttrium-90 for radioimmunotherapy. J Nucl Med 1987; 28: 1465-1470.
12. Larson SM. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J Natl Cancer Inst 1991; 83: 1602-1604.
13. Reilly R. Radioimmunotherapy of malignancies. Clin Pharm 1991; 10: 359-375.
14. Gansow OA. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 1991; 18: 369-381.
15. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconj Radiopharm 1991; 4: 85-97.
16. 2-. Radiochim Acta 1993; 60: 1-10.
17. Kumar K, Magerstaedt M, Gansow OA. Lead(II) and bismuth(III) complexes of the polyazacyeloalkane-N-acetic acids: 1,4,7-triazacyclonoane-N,N′, N″-triacetic acid, 1,4,7,10-tetra-azacyclodecane-N,N′, N″,N‴-tetraacetic acid, and 1,4,8,11-tetra-azacyclodecane-N,N′, N″,N‴-tetraacetic acid. J Chem Soc. Chem Commun 1989; 3: 145-146.
18. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990; 50: 4221-4226.
19. McMurray TJ, Brechbiel MW, Kumar K, Gansow OA. Convenient synthesis of bifunctional tetra-aza macrocycles. Bioconjugate Chem 1992; 3: 108-117.
20. Chaves S, Delgado R, Frausto Da Silva JJR. The stability of the metal complexes of cyclic tetra-aza tetra-acetic acids. Talannta 1992; 39: 249-254.
21. Colcher D, Esteban JM, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, Larson SM, Schlom J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987; 47: 1185-1189.
22. Nieroda CA, Mojzisik C, Sardi A, Farrar WB, Hinkle G, Siddiqi A, Ferrara PJ, James A, Schlom J, Thurston MO, Martin EW. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surg Gynecol Obstet 1989; 169: 35-40.
23. 111In-CYT-103). Antibody Immunoconj Radiopharm 1989; 2: 257-269.
24. Renda A, Salvatore M, Sava M, Landi R, Lastoria S, Coppola L, Schlom J, Colcher D, Zannini G. Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum. Preliminary report with a new monoclonal antibody B72.3. Dis Colon Rectum 1987; 30: 683-686.
25. Carrasquillo JA, Sugarbaker P, Colcher D, Reynold RC, Esteban J, Bryant G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J, Larson SM. Radioimmunoscintigraphy of colon cancer with I-13 I-labeled B72.3 monoclonal antibody. J Nucl Med 1988; 29:1022-1030.
26. Schlom J, Colcher D, Milenic DE, Horan Hand P, Greiner JW, Kuroki M, Thor A, Molinolo A, Ohuchi N. TAG-72 as a tumor marker. In: Sell S, ed. Serological cancer markers. Totowa, NJ: The Humana Press; 1992: 387-416.
27. Colcher D, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199-3203.
28. Colcher D, Keenan AM, Larson SM, Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984; 44: 5744-5751.
29. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconj Chem 1990; 1: 59-65.
30. Esteban JM, Schlom J, Gansow OA, Atcher RW, Brechbiel MW, Simpson DE, Colcher D. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987; 28: 861-870.
31. Clem R, Lambrecht RM, Mirzadeh S, Pippin CG, Brechhiel MW, Roselli M, Gansow OA, Colcher D. Radiochemistry of lead-203 for radiolabelling antibody conjugates. J Labeled Compd Radiopharm 1991; 30: 327.
32. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-terachloro-3α,6α-diphenylglycouril. Biochem Biophys Res Commun 1978; 80: 849-857.
33. Colcher D, Minelli, FM, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988; 48: 4597-4603.
34. Tom BH, Rutzky LP, Jakstys MM. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976; 12: 180-191.
35. Humm J. Dosimetric aspects of radiolabeled antibodies for tumour therapy. J Nucl Med 1986; 27: 1490-1497.
36. 212Bismuth linked to an anti-pancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988; 80: 449-152.
37. 224Ra. Appl Radiat Isot 1988; 39: 283-286.
38. III complexes. J Org Chem 1993; 58: 1955-1958.
39. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DE, Meares CF, Yuan A, Welborn JL, DeNardo JL. Yttrium-90/indium-111-DOTA-peptide-chimeric E6: pharmacokinetics, dosimetry, and initial results in patients with incurable breast cancer. Anticancer Res 1997; 17: 1735-1744.
40. Camera E, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai EH, McMurray TJ, Gansow OA, Pastan I, Paik CH, Carrasquillo JA. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 1994; 35: 882-889.
41. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, Colcher D. Comparative biodistributions of yttrium-and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989; 30: 672-682.
42. Roselli M, Schlom J, Gansow OA, Brechbiel MW, Mirzadeh S, Pippin CG, Milenic DE, Colcher D. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Nucl Med Biol 1991; 18: 389-394.
43. 212Bi for α-particle mediated radioimmunotherapy. J Chem Soc. Chem Commun 1991: 1169-1170.
44. Gansow OA, Brechbiel MW, Pippin CG, McMurry TJ, Lambrecht R, Colcher D, Schlom J, Roselli M, Strand M, Huneke R, Ruegg CL. Lead and bismuth complexes of functionalized DTPA ligands and of the polyazacycloalkane-N-acetic acid DOTA. Utility for radioimmunoimaging and radioimmunotherapy. Antibody Immunoconj Radiopharm 1991; 4: 413-125.
45. Gilles SD, Wesolowski J. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Human Antibodies and Hybridomas 1990; 1: 47-54.
46. 2 domain-deleted recombinant immunoglobulin. Int J Cancer 1993; 53: 97-103.
47. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. Science 1988; 242: 423-426.
48. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191-1197.
49. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408.
50. Milenic DE, Yokota T, Filipula DR, Finkelmun MAJ, Dodd SW, Whitlow M, Snoy P, Schloni J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cinieer Res 1991; 51: 6363-6371.
51. Slavin-Chiorini DC, Kashmiri SVS, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, Horan Hand P. Biologic properties of chimeric CH1 domain-deleted and CH2 domain-deleted anti-carcinoma immunoglobulins. Cancer Res 1995; 55: 5957s-5967s.